Drug Trial Radar · NCT06169579
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
96
Planned (sponsor's estimate)
Start
Feb 4, 2024
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shenzhen NewDEL Biotech, Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.; Sun Yat-Sen University Cancer Center
- First posted
- Dec 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection). The study also investigates how the drug is absorbed and processed in the human body.
Conditions
- Advanced Solid Tumor
Interventions
ND-003 tabletsDrug
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tabletsDrug
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tabletsDrug
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tabletsDrug
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tabletsDrug
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tabletsDrug
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tabletsDrug
ND-003 tablets will be administered orally over continuous 28-days cycles.
ND-003 tabletsDrug
ND-003 tablets will be administered orally over continuous 28-days cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity (DLT)Time frame: 4 days after single oral administration and the first cycle of multiple administration (28 days)
- Maximum tolerated dose (MTD)Time frame: 4 days after single oral administration and the first cycle of multiple administration (28 days)
- Adverse Events (AE) assessed by CTCAE ver5.0.Time frame: through study completion, an average of 1 year
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
the First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
the first hospital of Lanzhou University
Lanzhou, Gansu, China
Sun Yat-sen University cancer center
Guangzhou, Guangdong, China
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China
Zhanjiang Central Hospital, Guangdong Medical University
Zhanjiang, Guangdong, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
the Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Tongji Hospital Tongji Medical College of HUST
Wu’an, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Shandong Cancer Hospital & Institute
Jinan, Shandong, China
Linyi Cancer Hospital
Linyi, Shandong, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
The Second People's Hospital of Neijiang
Neijiang, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.